BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 23408429)

  • 21. Trailing TRAIL Resistance in Human Breast Adenocarcinoma Cells with Trichostatin A and Zebularine.
    Wong SHM; Fang CM; Loh HS; Ngai SC
    Anticancer Agents Med Chem; 2023; 23(7):817-831. PubMed ID: 36380402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
    Kim JH; Ajaz M; Lokshin A; Lee YJ
    Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
    Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
    Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
    Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH
    J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
    Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha.
    Johnson BW; Cepero E; Boise LH
    J Biol Chem; 2000 Oct; 275(40):31546-53. PubMed ID: 10913120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis.
    Gillespie S; Zhang XD; Hersey P
    Mol Cancer Ther; 2005 Apr; 4(4):668-76. PubMed ID: 15827341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria.
    Thomas WD; Zhang XD; Franco AV; Nguyen T; Hersey P
    J Immunol; 2000 Nov; 165(10):5612-20. PubMed ID: 11067917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-6 sensitizes TNF-α and TRAIL/Apo2L dependent cell death through upregulation of death receptors in human cancer cells.
    Sano E; Kazaana A; Tadakuma H; Takei T; Yoshimura S; Hanashima Y; Ozawa Y; Yoshino A; Suzuki Y; Ueda T
    Biochim Biophys Acta Mol Cell Res; 2021 Jun; 1868(7):119037. PubMed ID: 33839168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
    Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
    Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.
    Li WF; Dai H; Ou Q; Zuo GQ; Liu CA
    Tumour Biol; 2016 May; 37(5):5885-95. PubMed ID: 26589417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LIGHT sensitizes IFN-gamma-mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondria pathways.
    Zhang MC; Liu HP; Demchik LL; Zhai YF; Yang DJ
    Cell Res; 2004 Apr; 14(2):117-24. PubMed ID: 15115612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lobaplatin inhibits breast cancer progression, cell proliferation while it induces cell apoptosis by downregulating MTDH expression.
    Tian W; Hao S; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Chen Y; Li Z; Luo D
    Drug Des Devel Ther; 2018; 12():3563-3571. PubMed ID: 30464390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax.
    Jia L; Patwari Y; Kelsey SM; Newland AC
    Biochem Biophys Res Commun; 2001 May; 283(5):1037-45. PubMed ID: 11355877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
    Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S
    Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
    Wang S; El-Deiry WS
    Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.